• TCCR closed on acquisitions of subsidiaries Correlate and Solar Site Design on December 28, 2021
• The company has filed with the SEC to change its name to Correlate Infrastructure Partners Inc.
• TCCR subsidiaries have a project pipeline of over $100 million, with more than $20 million in awarded backlog
• The company’s total addressable market is more than 5.9 million commercial buildings in U.S., representing a market value of $290 billion in 2022

Correlate Infrastructure Partners (OTCQB: TCCR), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. TCCR is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale. The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate. TCCR announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. TCCR currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network. The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. TCCR believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally. TCCR has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current TCCR ticker symbol until changes are approved. Subsidiaries Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios. Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (“NABCEP”), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace. Market Outlook TCCR is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector. Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed. In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. TCCR’s financial instruments and software breakdown this issue known as the “split incentive,” unlocking the majority of the addressable market. Management Team TCCR has in place a nationally recognized management team that has been active in the energy market since 2005. Todd Michaels is President and CEO of TCCR and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems. Channing Chen is CFO at TCCR and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space. David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky. Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA). Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021. Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington. Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts. For more information, visit the company’s website at www.CorrelateInfra.com. NOTE TO INVESTORS: The latest news and updates relating to TCCR are available in the company’s newsroom at https://ibn.fm/TCCR

• HENC is focusing on expansion of current operations, future growth in industry
• Company aims to be a low-cost, nationally and internationally branded company, become true multistate operator (“MSO”)
• Recent podcast provides overview of company’s strategic plans, important milestones

Key acquisitions and investments have played an essential role in Hero Technologies’ (OTC: HENC)  strategic business plan and operations. As a featured guest during a recent episode of the Bell2Bell Podcast (https://ibn.fm/J3DGC), company CEO Gina Serkasevich discussed HENC’s careful expansion moves. In 2020, “both Highly Relaxing and the assets of V Brokers, under Veteran Hemp Co., were acquired,” said Serkasevich as she discussed the company with Bell2Bell host Stuart Smith. “Both of these entities gave Hero a foot in the door to establish itself as a cannabis player. Since then, our biggest advancement was becoming a majority stakeholder in BlackBox Systems and Technologies.” In brief, she continued, “BlackBox is an aeroponic cannabis cultivation system that provides many efficiencies in growing and cultivating large flowering plants in environmental growth chambers, all based on proprietary aeroponic technology.” During the interview, Serkasevich noted that Hero Technologies is a relatively newly formed cannabis operator. “The company is focusing on expansion of its current operations and its future growth in industry,” she said. “Having said that, the business model includes licensing and processing operations at facilities, sale of products and technological development,” she continued. HENC’s “objective is to be a low-cost nationally and internationally branded company and become a true MSO, or multistate operator.” Serkasevich noted that the backgrounds of HENC executives are ideally suited for the company’s success and growth. “I’m primarily in the accounting and finance area,” she said. “I was CFO of Holloman Energy Corporation, the company that was purchased by Hero Technologies to start the cannabis operations. They asked me to come on board and help them through their transition and then asked me to be CEO, as well, going forward. “We also have Marc Kasabasic, the COO of BlackBox, in which Hero owns a majority investment,” she said. “He has worked as an R&D engineer and account engineer, and his research and experience over the years was applied to developing cannabis systems and aeroponic technology, which our BlackBox system is based upon.” Throughout the interview, Serkasevich offered additional insight into other members of HENC’s seasoned management team, as well as recent company milestones and strategic plans for upcoming months. Participating in the Bell2Bell Podcast is part of HENC’s sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Air purifiers can improve indoor air quality, help soothe allergy and asthma symptoms, and rid air of toxins.
• Kronos’s proprietary, medical-grade technology has been tested as the most effective clean-air solution on the market.
• An air purifier “may be the household investment to make this year” (“USA Today”)

The global pandemic has drawn attention to the fact that airborne particles can be dangerous, even life threatening. Kronos Advanced Technologies (OTC: KNOS) has developed one of the most effective air purifiers available today. One study attributed over two million deaths annually to indoor air pollution (https://ibn.fm/pwSst). Air purifiers are part of the solution because they “greatly improve indoor air quality in large and small spaces alike,” reports a recent “USA Today” article (https://ibn.fm/ewvyU). “Indoor air pollution is a risk factor for several of the world’s leading causes of death, including heart disease, pneumonia, stroke, diabetes and lung cancer,” reports Our World in Data. “We see that it is one of the leading risk factors for death globally. According to the Global Burden of Disease study, 2.31 million deaths were attributed to indoor pollution in the latest year.” The “USA Today” article concurs, noting that “air quality is a serious issue that has made headlines over the past year as concerns grow around filtering contaminants like wildfire particulate matter and viruses from the air we breathe. While wearing face masks to protect from the coronavirus is ever on the mind, the air quality of your home is often overlooked. Fuel-burning appliances, deteriorating insulation, newly installed carpets, household cleaning products and outdoor air pollution are just a few of the sources of unhealthy air quality inside, where you live, eat and sleep.” The “USA Today” article points out that everything from asbestos and carbon monoxide to pesticides and lead can pollute stagnant household air, resulting in short- and long-term health problems. Issues arising from inadequate ventilation, the article explains, can range “from mild allergy-like symptoms to respiratory diseases and cancer.” Fortunately, “air purifiers can help remove or reduce pollutants by using a combination of physical filters, devices, chemicals and techniques. By doing so, air purifiers can improve the indoor air quality of your home, help soothe allergy and asthma symptoms, and get rid of toxins in the air.” Thanks to the array of benefits provided by air purifiers, the air purifier market space is growing. A recent Grand View Research report noted that the U.S. air purifier market was estimated at $2.17 billion in 2020 and is expected to grow at a compound annual growth rate (“CAGR”) of 8.6% from 2020 to 2028. The article pointed to increasing pollution levels and the rising prevalence of airborne diseases in the nation as the reasons behind rising product demand (https://ibn.fm/eWKJO). Kronos is making its presence felt in the growing sector with its proprietary, medical-grade technology, which has been tested as the most effective clean-air solution on the market. The Kronos AIR 5G filters particles down to .0146 micron, far beyond the 3 microns of a traditional HEPA filter. And Kronos air purifiers do more than collect air pollutants — using approximately 30,000 volts, the Kronos AIR 5G air purifier destroys 99.99% of all airborne bacteria, mold and virus particles. “So, are air purifiers worth it?” “USA Today” asks. “The short answer is yes, because they work just as they’re intended. Several studies have shown that air purifier usage can have a mild to moderate positive effect on air quality and, therefore, personal health. For this reason, an air purifier may be the household investment to make this year.” For more information about Kronos(R) AIR 5G(R) patented air-purifier technology and to purchase products, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

Life science executives are invited to attend the 2nd Real World Evidence and Market Access Symposium being held as a virtual event on April 11-12, 2022. The event is hosted by DGE, a leading global event management company that caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, health care, medical devices, and allied industries. The event centers around discussions, keynotes and sessions about the latest advances and best practices for harnessing real-world data insights that are productive for patients, payers and providers. Organizations can strengthen their business and reimbursement strategies by identifying and accessing the correct data, as well as understanding how to leverage secondary data for greater efficiency in clinical trials. The first step involves identifying the relevant data that will eventually pave the path for providing the right kind of treatment to the patients. This high-quality data will prove pivotal in determining which line of treatment is approved, reimbursed and prescribed. The forum will feature reputed dignitaries with excellent knowledge of RWE and how it can be used across a spectrum of clinical development, regulatory approval and access. The panelists will also share insights into how to ensure greater transparency in designing protocols, collect the right kind of data, and ensure its usefulness while addressing patient needs. Some important topics to discuss include:

• Improve scientific communication and build value maps for specific patient demographics
• Collaborating data while working with electronic health records, medical claims and patient registries
• Learn how RWE is being utilized in oncology plus RWD and expanded access programs
• Hear from the experts about what to do and what not to do working with FDA
• Leverage the insights learned from RWD to make trials more inclusive and diverse
• Access the evolving RWE for COVID 19 treatments to inform critical decision making

The 2nd Real World Evidence and Market Access Symposium will witness stalwarts across a spectrum of fields including data analytics, regulatory affairs, world data, evidence platforms/solutions, trial management software, data management software, digital platform technology, CROs, artificial intelligence, and machine learning. Join this symposium to learn how to overcome the challenges faced in using RWE to complement and innovate clinical trials. To learn more, please visit https://ibn.fm/SsROd.

• While appearing on The Jesse Tee Show, the company’s co-founder and CEO, Matt Stang, shared his professional background, Delic’s history, its growth, and its plans going forward
• Mr. Stang attributes its success to understanding where opportunities and people connect, how to make things win-win for all people, and giving customers value
• Founded in 2016, Delic Holdings Corp now has a market cap of $4.32 million as of March 2022

Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been at the forefront of reframing the psychedelic conversation. It has also remained committed to bringing science-backed benefits of psychedelics to the health industry, hence its position as a leading psychedelic wellness platform. To offer insights into the company’s growth, Matt Stang, Delic’s co-founder and chief executive officer (“CEO”), appeared on The Jesse Tee Show, a growth-mindset broadcast whose aim is to teach anyone hunting greatness the secrets to success. The show highlights top entrepreneurs, athletes, thought leaders, and creators, who walk the audience through their stories and their path to success (https://ibn.fm/Fb5PW). Mr. Stang touched on his professional background, highlighting how his senior thesis in college earned him an internship at High Times. This leading counterculture publication would later become the voice for the cannabis industry. Upon joining this enterprise, Mr. Stang became the director of its marketing and sales arm before buying the owner’s position in 2010 and becoming its driving force. Mr. Stang then grew High Times into a $20 million a year business, an achievement that he attributed to “Understanding where opportunities and people connect, how to make things win-win for all people and giving them real value” (https://ibn.fm/Fb5PW). Going on to become co-founder and CEO of Delic, headquartered in Vancouver, Stang and the company take pride in its comprehensive three-pronged ecosystem of Ketamine Wellness Centers (“KWC”), media properties, and DELIC Labs, a federally-authorized research facility. As of March 2022, the company had a market cap of $4.32 million, with a trailing 12-month (“TTM”) revenue of $3.6 million (https://ibn.fm/HaC3d). The interview also touched on the therapeutic potential of psychedelic compounds. Mr. Stang was keen to note that Delic recognizes this potential and is capitalizing on it to create value for its shareholders while also offering a solution to individuals dealing with mental health conditions. It is projected that by 2026, the psychedelic drugs market will be valued at $6.3 billion, up from $3.2 billion in 2021. This will represent a CAGR of 14.5%, mainly driven by regulatory support in the sector, widespread public awareness, and the overall growth in demand for psychedelic drug-assisted psychotherapy (https://ibn.fm/fTSah). Delic realizes this opportunity, hence its investment in research and development (“R&D”) and its push to reframe the psychedelic conversation. The company has also been strategic with its acquisitions, having closed the purchase of Seattle-based Homestead Book Company back in 2021 in a move that sought to increase the company’s psychedelic media distribution. Going forward, Delic looks to grow its intellectual property through more research. It also looks to provide education and high-quality products for the masses, particularly those struggling with mental health issues. View the full interview at https://ibn.fm/Y5ge7. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Artificial intelligence-enhanced security devices and big data collection are gaining popularity as means for strengthening companies’ footprints, particularly in response to criminal activity that can otherwise weaken operations
• Knightscope is a Silicon Valley-based company developing Autonomous Security Robots (“ASRs”) in response to America’s security needs, delivering a variety of models that observe and report on activity at client properties using powerful technological services
• Knightscope completed public listing on the Nasdaq Exchange in January 2022, enhancing awareness of its products and generating new inquiries about the nature of its services
• The company has taken note of its successes with its clients, and recently provided Q&A responses to inquiries from potential clients about the ASRs’ effectiveness

Mass-victim violence has become an almost normalized part of the American experience, so much so that it appears to attract little notice unless large numbers of the victims die. A recent report in Utah’s Deseret News noted nine mass shootings that had occurred across the country during the weekend as an example, part of the 107 such incidents that had occurred with minimal spectacle by March 23 (https://ibn.fm/FEt1t). Autonomous security robot (ASR) developer Knightscope (NASDAQ: KSCP) has been perfecting its craft in attempting to make the country safer through AI-empowered vigilance and a physical presence since April 2013, when outrage over a deadly attack on Boston Marathon runners and the tragic mass shooting of children at Connecticut’s Sandy Hook Elementary School led Knightscope’s founders to begin building robotic sentries that could monitor client properties 24/7, 365 days a year. As Knightscope’s profile has grown, particularly as a result of its trading launch on the Nasdaq exchange in January (https://ibn.fm/Mbgg7), the company has fielded a number of questions from prospective clients regarding the performance of its ASR robots and their competitiveness in a rising industry segment. The following are some of its responses to those inquiries:

1. What is the key advantage Knightscope’s technology offers to clients?
2. The number one benefit offered by Knightscope’s Autonomous Security Robots (“ASRs”) is physical deterrence. People doing bad things do not want to get caught. Knightscope provides intelligent eyes and ears on the ground. Its ASRs deliver unprecedented levels of situational awareness, actionable intelligence, and a force multiplier to augment security and public safety programs in tandem with local emergency response services. And all of this at a significant cost savings when compared with standard personnel models.
3. There’s a lot of security technology out there. What makes Knightscope stand out versus other options?
4. With 360-degree high definition video and a number of other onboard sensors that monitor, analyze, record, and report situations on the premises using powerful technological capabilities, the ASRs reduce the potential for conducting illegal activity in secrecy. Essentially, they provide an increased incentive for bad actors to avoid the risk of being caught in a crime within the vicinity of an ASR. This benefit does not exist with other security technologies.
5. What are the specific types of “robots” that Knightscope offers, and what are the differences between them?
6. – K1 Stationary Indoor/Outdoor ASR – K3 Indoor Mobile ASR – K5 Indoor/Outdoor Mobile ASR (Each robot is sized and equipped for their respective indoor, outdoor, mobile, or stationary missions.)
7. What are these robots designed to do, and what do they not do?
8. Knightscope’s ASRs are intended to augment a security program and work alongside humans. Robots are good at performing the boring, routine, and monotonous work that can sometimes be dangerous in a security setting. Humans on the other hand are great at personal service, empathy, and hands-on activities. In the ideal partnership, Knightscope’s robots observe and report, and the humans are freed up to investigate what is reported. The ASRs provide a friendly and communicative interaction with their environment, while humans are then better informed to take appropriate hands-on action if needed.
9. What kind of control does a client actually have over these security robots, and how is it done?
10. The clients have a great deal of control over their ASRs including, but not limited to, scheduling patrol routes, broadcasting messages, communicating via two-way intercom, using strobe light and patrol sounds, and stopping or parking the ASR, all of which is done through the browser-based user interface included with the service called the Knightscope Security Operations Center (“KSOC”).
11. What are some examples of how your robots are currently being used?
12. Knightscope’s ASRs are used to patrol parking lots and parking structures, banks, corporate campuses, casinos, hospitals and other healthcare facilities, transportation depots, and many other client properties from Hawaii to Rhode Island. Their uses vary from client to client, but a few examples include deterring criminal activity and vagrant trespassing, providing budget relief, improving workplace violence prevention, and watching over high-value assets.
13. How do I know how many of these robots I will need, and how expensive is it?
14. Knightscope’s Client Development team is made up of highly experienced professionals that walk each client through the process of determining needs, deciding which ASR(s) best suit those needs and then recommending appropriate placement and patrol paths to help the client resolve pain points. Knightscope’s all-inclusive service is incredibly affordable at $3 to $9 per robot per hour.
15. What evidence is there that all this technology really works better than just hiring security guards, etc.?
16. Have a look at our crime fighting wins and statistics here: https://www.Knightscope.com/crime/

As an example of client satisfaction, Huntington Park, Calif.’s, city council extended its municipal contract with Knightscope last year for an ASR that patrols a park of concern to the city, responding to the chief of police’s recommendation. Video of the discussion is available here: https://ibn.fm/5gk3q For more information about Knightscope, visit the company’s website at www.Knightscope.com, and if you are considering subscription service you can request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

• Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction
• Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trials
• The company is targeting nicotine addiction in tobacco smokers
• Mydecine is also advancing its evaluation of other drug candidates with pending patents to enhance its existing products

Medical-use psychedelic drug product developer Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is making gains in its efforts to bring novel products to clinical trial for the potential treatment of addictive behaviors such as unhealthful smoking of tobacco-derived nicotine, announcing March 24 that an Institutional Review Board (“IRB”) has granted conditional approval for a new smoking cessation trial planned this summer (https://ibn.fm/43cgH). Mydecine plans to begin patient recruitment in a multi-site Phase 2b clinical trial of its lead drug candidate MYCO-001, 99% pure psilocybin, once investigational new drug (“IND”) approval has been granted by the U.S. Food and Drug Administration (“FDA”). MYCO-001 would be used as a therapeutic, in conjunction with therapy, for nicotine-dependent individuals in partnership with Dr. Matthew Johnson of Johns Hopkins University, who will oversee the psychotherapy regimen. The planned placebo-controlled study is designed to evaluate the safety and efficacy of psilocybin-assisted psychotherapy utilizing MYCO-001, building on prior smoking cessation studies Johnson and his team conducted that showed 59% of participants who received psychedelic-assisted therapy remained abstinent from smoking at 12 months, compared to 28% of patients who received a transdermal nicotine patch, according to the company (https://ibn.fm/RE3nq). According to the Centers for Disease Control and Prevention (“CDC”), about 12.5% of the nation’s adult population currently smoked cigarettes as of 2020, amounting to about 30.8 million adults, 16 million of whom live with a smoking-related disease (https://ibn.fm/8S09q). Mydecine representatives met with the FDA last month, and are preparing their finalized IND application as well as a request for Breakthrough Therapy designation that would grant MYCO-001 the possibility of an accelerated approval process. The company plans to submit both applications in Q2 2022 and is hopeful that the FDA will green-light the effort within 30 days. The IRB’s approval is a conditional ethical review finding that will allow Mydecine to proceed once it has the FDA’s positive reply to its IND filing. “We are beyond excited to share the news of our conditional IRB approval,” CEO Josh Bartch stated in the company’s announcement (https://ibn.fm/dNVrU). “Upon the near-term clearance of our IND application, which is wholly owned by Mydecine, we will be the first commercial IND approved utilizing psilocybin for the indication of smoking cessation, and one of a small number of organizations with a commercial FDA IND approval, alongside COMPASS Pathways, MindMed, and Usona, for a Phase 2 or later stage study assessing a psychedelic compound for any indication. We have a strong patent and regulatory strategy to support this initiative as well as further subsequent approvals.” The Phase 2b study is contemplating a primary endpoint of six months, indicating it could publish data as early as Q4 2023, according to the company. “Mydecine is currently working our second-generation drugs through the clinical pipeline to replace our first generation with a more superior, more refined, more scalable second generation of psychedelic medicine,” Bartch said in a video presentation the company posted to YouTube last month (https://ibn.fm/ADxjy). “We’re looking at known efficacious MYCO-001 single molecule psilocybin that we feel is drastically better than what’s currently available on the marketplace (for treating smoking cessation).” The basis for the drug has already been established in nature, Chief Scientific Officer Rob Roscow said in the video. “Mydecine takes a very nuanced approach to drug development,” Roscow said. “As opposed to designing molecules from scratch that may or may not affect a condition of interest, we’re taking molecules from nature, such as psilocybin, that have already shown strong efficaciousness in the conditions that they’re treating or being studied in treating, and then we’re making very purposeful modifications — changes or improvements to these. By building off of the templates that are provided by nature to us, we really can be confident of the value of these molecules moving further in the pipeline.” The research-based company is also working to develop and commercialize other drug candidates, such as a patch-delivered tryptamine compound known as MYCO-004 and compounds MYCO-005 and MYCO-006 that target increased safety and stability in their respective psilocin and MDMA (Ecstasy) analogs, according to an investor presentation prepared by the company (https://ibn.fm/o7Bpl). “These molecules include enhancements we believe are critical for psychedelic medicine to become accepted and adopted into traditional medical settings,” a March 7 management statement regarding MYCO-005 added (https://ibn.fm/de821). “MYCO-005 includes a novel psilocin analog that could potentially be considered a heart-safe microdose drug by eliminating a possible known risk factor. Although microdosing has been gaining popularity in mainstream media as a possible treatment for indications such as ADHD, depression and anxiety, more research is needed to confirm the safety and efficacy of this method. We believe our MYCO-005 family of molecules are safer than what’s currently available.” A new subscription agreement for the sale of additional investor shares announced March 18 is designed to provide the company with “enhanced flexibility and access to capital should future additional financing be required, and it may be activated if and as deemed appropriate,” according to the company (https://ibn.fm/F0TEl). For more information on Mydecine Innovations Group, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

Fintech, Healthcare, pharma, technology, finance, infrastructure, and allied companies and investors are invited to attend the Virtual Growth Conference, being held on March 28-30, 2022, as a virtual event. The year 2022 opens up opportunities for traders and investors and this Virtual Growth Conference 2022 offers the perfect stage for networking and understanding the future scope of business. The Virtual Growth Conference is one of the leading investor conferences, organized by M-Vest Events, powered by the Maxim Group LLC, a leading investment bank. The group serves investors, issuers and industry stalwarts, allowing them to interact on an excellent online forum. The Virtual Growth Conference will offer executives, companies and investors a networking stage while connecting companies with potential investors. The event is organized only for members and offers a brilliant user experience. At the virtual conference, new companies, as well as established firms, can engage with investors through one-on-one discussions, presentations and fireside chats. The 3-day event offers fireside chats, panel discussions, live round tables, and Q&A with company heads moderated by Maxim Research Analysts, across a wide spectrum of business sectors featuring approximately 300 companies. Though virtual, these events offer an interactive forum for capitalists and professionals, industry stalwarts shareholders, leaders & executives from a wide range of sectors including Autonomous Vehicles, Biotech, Blockchain Technology, CBD / Cannabis, Clean Energy, Digital Media, Electric Vehicles, Financial Services, Fintech & REITS, Online Gaming & Entertainment, Healthcare, Health & Wellness, Healthcare IT, Infrastructure, Shipping and Technology / Media / Telecom. Young companies looking for potential investors can leverage this phenomenal opportunity to gain visibility and get discovered by giant firms. This Growth Conference will be held as a live streaming online conference, in keeping with the current health and safety protocols. Day 1 is dedicated to the healthcare sector, with discussions and fireside chats being held by pharma, medical and life science companies on a wide gamut of topics. On day 2, industries from the tech and finance sectors will hold presentations and fireside chats. On the last day, miscellaneous companies will come together and interact in the virtual environment of the conference. At the Growth Conference, presenting companies introduce and discuss the company goals and share insights on specific topics of relevance. These events are tailored to offer an engaging experience to a seasoned crowd of investors and executives. To learn more, please visit https://ibn.fm/cg5yX

• Cannabis product cultivator Flora Growth Corp. operates a premium growing facility in central Colombia and has received a growing list of authorizations to export its cannabis products for varied health and wellness purposes
• Flora Growth’s authorized distribution of low-THC CBD cannabis derivatives has been recently expanded to include a quota of up to 43,600 kg of products with high-THC cannabis
• Flora also reached agreement with Israel-based DNO Group to further commercialize Flora’s Mind Naturals skin care products through potential distribution outlets in Hong Kong, with plans to build into outlets in Israel and India later
• Colombia has also authorized the company to add four new genetic strains to its high-yield THC and high-yield CBD (cannabidiol) product portfolio for use in commercial products

Global cannabis brand builder Flora Growth (NASDAQ: FLGC) solidified distribution deals this month that expand the amount of high-THC (tetrahydrocannabinol) dry flower and cannabis derivative products it is permitted to export from its Colombia base of operations and open new market opportunities for its Mind Naturals skin care products in Asia and Eastern Europe. Flora Growth is an internationally focused company with all-outdoor cultivation facilities in central Colombia where growing conditions are some of the most ideal in the world. Its 100-hectare (about 247-acre) Cosechemos facility benefits from a government that is increasingly friendly to cannabis production and transportation, having legalized exportation last year of dried flower for food, textile and medicinal purposes and having established the regulations just last month (https://ibn.fm/V1QEE). On March 15, the company announced that the Colombian government’s Ministry of Health and Social Protection expanded authorization on its product exports to include not only cannabis derivative products with less than 1% of the psychoactive THC compound but also up to 43,600 kg of products with high-THC cannabis that are designed for health and wellness uses and not the recreational-use market. “With receipt of this expanded 2022 quota, we can now work towards fulfilling previous agreements, including the agreement with Artos Ltd. to send high-THC cannabis to Israel and other legal markets,” Flora’s Chief Commercial Officer Jason Warnock stated (https://ibn.fm/GOkWX). “The changes to the export quota this year represent a major milestone for Colombian exports and provide a clear pathway for the region to make a significant global impact on the cannabis industry.” The government’s Agricultural Institute (“ICA” or Instituto Colombiano Agropecuario) also authorized Flora to add four additional strains to its high-yield THC and high-yield CBD (cannabidiol) product portfolio, expanding potential commercialization opportunities for the company. In the meantime, the new distribution agreement regarding its Mind Naturals premium CBD skin care brand teams Flora with Israel-based DNO Group, a company with over 50,000 points of sale throughout Asia as part of its broad global reach. Together, the companies will use an omnichannel approach including brick and mortar retail, e-commerce and other wholesale markets to market Mind Naturals in Hong Kong with anticipated expansion to Israel and India during second-phase growth, according to the company (https://ibn.fm/XTTGJ). The agreement builds on Mind Natural’s 12-product retail launches through Walmart.com and Mexico’s Coppel, which has a network of 1,253 stores in the country (https://ibn.fm/0bRhq), and initial exports to Spain. “With quality ingredients and a thoughtful customer experience, Mind offers something different in this competitive space. We look forward to working with DNO to bring this unique offering to key markets around the world,” CEO Luis Merchan stated. For more information, visit Flora Growth’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The inflation rate in the United States for the 12 months ending February 2022 was 7.9%, the highest it has been since January 1982
• In addition to the rise in inflation, the price of gold has risen to levels not previously seen
• StraightUp Resources Inc. looks to capitalize on this growing price and looks to benefit from it given its investments in properties with a rich history of gold production

Although today there are a number of investments being touted as the best hedges against inflation, the current high rate of inflation, and its long-term prospects for continuing, together with a variety of geopolitical risks, have led investors to take another look at gold. The current inflation rate in the United States for the 12 months ending February 2022 stood at 7.9%, the highest since January 1982 (https://ibn.fm/uSmXi). In addition, the inflation-adjusted value of gold has been touching record high levels. It is further projected that the value will continue to rise given the uncertainty in Europe with the Russia-Ukraine conflict (https://ibn.fm/j6gF0). StraightUp Resources (CSE: ST) (OTCQB: STUPF) stands to be one of the beneficiaries of the growth in gold’s value. With its flagship property located in the Red Lake Mining District of Ontario, known for over 30 million ounces of historic gold production, this enterprise is set to benefit significantly from the surge in the metal’s value, and shareholders are looking for reflected growth in the company’s share price and the overall value of the enterprise. StraightUp has been committed to mineral exploration and acquiring mineral assets in North America. Its goal has been to maximize shareholder wealth through mineral discoveries at projects with the best potential, maintaining long-lasting partnerships, continued acquisitions, development, and exploration of mineral resource properties in North America. This has seen it acquire strategic properties rich in gold, including the 10,000-hectare RLX projects, sharing a common border with critical properties such as Evolution Mining, Pacton Gold, Dixie Gold, and Great Bear Resources properties. In addition, the company’s Belanger Project has seen three significant exposures of gold, copper and silver over a 2,000-hectare property, with similarly promising results showing up in the Ferdinand Gold Project and the Bear Head Gold Project. StraightUp’s management is optimistic about the future and the value that it is expected to generate. Earlier this year, the company received its early exploration permit (“PR-21-000261”) from the Ministry of Northern Development and Mine, Natural Resources and Forestry (“NDMNF”), granting it the authority to proceed with mechanized drilling and geophysical surveys (https://ibn.fm/K8jdd). The company plans to capitalize on this permit to develop and test gold targets, starting with detailed data compilation, including interpretation of the high-resolution airborne geophysical surveys conducted in 2021. With the price of gold going up, the company’s exploration efforts are slowly proving themselves invaluable. In addition, it is validating its exploration goals, and the management is confident that the investments made so far will pay off significantly as time progresses. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF